{"name":"UCB BIOSCIENCES GmbH","slug":"ucb-biosciences-gmbh","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Carbamazepine-Controlled Release","genericName":"Carbamazepine-Controlled Release","slug":"carbamazepine-controlled-release","indication":"Epilepsy / seizure disorders","status":"phase_3"},{"name":"Rotigotine transdermal patch","genericName":"Rotigotine transdermal patch","slug":"rotigotine-transdermal-patch","indication":"Parkinson's disease","status":"marketed"}]}],"pipeline":[{"name":"Carbamazepine-Controlled Release","genericName":"Carbamazepine-Controlled Release","slug":"carbamazepine-controlled-release","phase":"phase_3","mechanism":"Carbamazepine is an anticonvulsant that stabilizes neuronal membranes by blocking sodium channels, reducing repetitive neuronal firing and propagation of seizure activity.","indications":["Epilepsy / seizure disorders","Trigeminal neuralgia","Bipolar disorder"],"catalyst":""},{"name":"Rotigotine transdermal patch","genericName":"Rotigotine transdermal patch","slug":"rotigotine-transdermal-patch","phase":"marketed","mechanism":"Rotigotine is a non-ergot dopamine agonist that stimulates dopamine receptors in the brain to restore dopaminergic neurotransmission.","indications":["Parkinson's disease","Restless legs syndrome (RLS)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxPNzF3bUJrRHFEcFl0LXhWWW92NWpSdnZMZHJHcnNnejhBNVJjY19GYm84cklQTkE4YVRwTWhDQVFFUk9KQ0NwQ0Jzc05uSkZwWDlFbmR1cWlVeERVcFB5ZWthOUI5RlRBdWR6STRRUXJJQ1BTUDdXSWptcjU1UlJHWUdtclRGbC10VC1vcVF6QWNqVV9HM2pCcHVjX3BOeWY1NG9nWXhyaFFXSWJlUHpxTGdKOWF3SjRWczN2SkRaeVNLa2c?oc=5","date":"2026-03-04","type":"deal","source":"European Biotechnology Magazine","summary":"UCB licenses Antengene’s ATG-201 in $1.1B autoimmune masked T-cell engager deal - European Biotechnology Magazine","headline":"UCB licenses Antengene’s ATG-201 in $1.1B autoimmune masked T-cell engager deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0wJBVV95cUxPOThxR3QxTzRlRnBZOVVuVUUxZ0NqeXhudThyVS1rV0xMREROZTJGOTl5QXVDNkpvZE1KVk96ajJUMkJid2hvSExmcUNZTkx1ODdvclFHWHJtY1hubUwxTkFOS2tHUHNmQ1RvNVkxbDlIdGNMZ3NGSFhIN1cwQ3dTV21aUFRWX1RpdHp3Smdndm90S0ptdTIwcGE2X2lmY1JhaEMwZFNESWdkNGxVSTVYVXJHdVduU2MtNGpxdm1hYkRfWjItS0lCWHlsNmhtdFpQdW9FU0NsWnFfVnp0QUc0VXF3V045VkVPSWtlbXVCT3Rwa3dRMTZwSWtfQXotclZxY1F3ZlFfNW1HNzEtMnlHM1dJMFVtLTdFeU9xV1BVVXgxcXNlZ01abXYtT2dpMDBBLXBUdnNUU1BVSkVDVXlCMlV4dTZKdUQtT3QzVHdJMkdmbzg?oc=5","date":"2026-01-23","type":"regulatory","source":"Barchart.com","summary":"Rheumatoid Arthritis Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Eli Lilly and Company, Philogen, I-Mab Biopharma, Teijin Pharma, Revolo - ","headline":"Rheumatoid Arthritis Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsi","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0wJBVV95cUxNeWEyc0ZSQ29fczhyMHUxMG1ZUmk1YmM5bVdSOE1kOTFqQl9PRWZOV1FyMXJFdTZjSmNZdUwta3gySjJmN09xbkYydDhVQnRGU3E4RTJvb3Q1NnZSbzdLVmdoNTBhQUROT2hrbWRza3NFb2YzR1QtV3htZkFlbmNyWGM0anBEcXdzQ3NnZVpzdTVRX0FOenZJeDA1UVVWVTluai1yWS1QMWRWNExWTkxSMnBJZUdQUDE1Q1h1VGcyam1mdDlNbDJydTVTenUzZ1ZieWZkZGNKeVhJaXVway05RWxucnhjMkxMZFl4bkpleHhtaEJYQlhHXzhYcEt6LXpUVzVWLXdjUDFGbEl0UjBlenpORUp3Y3hqZFdUeFBzaW9XM2xnSV9IOG1VLXNQN3hZb1pPcEtfR0dZakZsRXFkeFBpdURTX3pDa1BXT1FpZjRmLXM?oc=5","date":"2025-09-17","type":"pipeline","source":"PR Newswire","summary":"Interleukin-13 Inhibitors Market Predicted to Surge During the Forecast Period (2025-2034) Due to Breakthrough Therapies in Atopic Dermatitis, Asthma, CRSwNP, and Others | DelveInsight - PR Newswire","headline":"Interleukin-13 Inhibitors Market Predicted to Surge During the Forecast Period (2025-2034) Due to Breakthrough Therapies","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowJBVV95cUxNelhGRWdNOUpyWkFNSHZzMml5MHFvYnpHMmVhN0RjRmZ6UW5WR0hMeTM2SG91enFaNUk0ODRmekxuQWxjMHo1eHRpRlR4ZXZLNFpIOEkzQTRMMnNDaWNiUXQtMFFON2VFSWRJUUp4MXUySklNUThyRXlVSlYyOEVyR1hENnBUT1gtQmtGTDE1clFDNmhYWWNGTG1VSVFWUXl1cnBSNW9Rdkdpa0FFU3RsWlZXVVVJc2VoOFZRZ1lPekVyTUtLZGNGM0cxMlZaQkstMFRzbkx5YVNHdzJmbm1qOEdKWFhQQ3dDNWFCZXJYS2JOUjhCM0Z2OVV0Z3NocUpVRTJSY3BKSzVoaVowOWpkZzROSXV3dkFVRm9EVVlxNmNPVmM?oc=5","date":"2025-04-08","type":"pipeline","source":"GlobeNewswire","summary":"Developmental and Epileptic Encephalopathies Market to - GlobeNewswire","headline":"Developmental and Epileptic Encephalopathies Market to","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxOaU9nTG9aOWh5TUowOFdWd1dpT193MXh5Q2J3VUxHWFYyS3pJZW1IdGFYbXQ0VUxHRXlPUUFNNEkxaFhKcXktSmJoQmt3U0EyQVZYTGlHQkl3NlZDRzlCQjhQZ0pRTW9JOW9HcXE2RnJ4VjJRMXhDc3NDandpOFkwaE1DRVcwYjB1VVZvZTM4UjA3dy15MUdOVFlCaXAySkk?oc=5","date":"2024-12-02","type":"pipeline","source":"worldpharmaceuticals.net","summary":"CBC, Mubadala complete acquisition of UCB’s mature business in China - worldpharmaceuticals.net","headline":"CBC, Mubadala complete acquisition of UCB’s mature business in China","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgJBVV95cUxQYXlpWWtJNGNLZHJEeWRMRnR6R0E2SVY5eElibzV2ZDlyaGZ0cDNLd3Z4V2hIVWpoZlA1LUw5SEd6SHRHbWNva1VQcUExU1FQN1lWV3pBN2M4aUktay16cGpCc2pPc2xsOWlwUzBvMXFGbmduaG5OdE1mZEM5aEdlN3BsNU1LNER4eWtScEpHb1hKUllUWm1OSndEM3MySmF6d3VPY0Q5ZVFjclBWUG5TMGNpODhhYWdiUlFQbV94T0g1T3RyZ2FnOWlhS0Z1c0xpNnExUGJBMTJfSGNGR01paGlveU5mazNqMV9JM1FIX1FlSzUwSjJ4VEtBWjVtWTVfTmpteW9n?oc=5","date":"2024-11-19","type":"regulatory","source":"PR Newswire","summary":"Systemic Lupus Erythematosus Clinical Trial Pipeline Gains Momentum as 120+ Key Companies at the Forefront | DelveInsight - PR Newswire","headline":"Systemic Lupus Erythematosus Clinical Trial Pipeline Gains Momentum as 120+ Key Companies at the Forefront | DelveInsigh","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwJBVV95cUxOUVVGN0pqSktYbDVqOE12LWFaV0gwY1dBaW4welk1X3FwakJsTnM2ZEZwLVZJOWl0RUFlWEVjTzZEaEpIcmJyR215U1dFaVJlaGM1cDV2eU1lNGRYaS1adUlUdjF0MjhVSUlab0IxVlg2SUdmMkVXRnV0enlPTTI0YmtVUzZvR3hseHIwLWtRejd3VXl5eXZEejZnQU02TWFCLXByT21vMTJxdGNqY2hDMWFreDFYVnVHbnVSWFVlNkxya3FaN2VIczMyMFNDSktFakNSMkRtWFZpUVRNNVh0cGt5N0ZGVEo0NU1jVjFhNzNWbHNOWENlQ3E4S0kyaDVZaWhTM3d3Z0RKdlBYLUd0dWg1ajd3a1pnU2pnc2hCSVNfREY4RXB0dVJjYUpSY3I3cWhxUDdfZw?oc=5","date":"2024-10-28","type":"trial","source":"GlobeNewswire","summary":"Complement Inhibitors Clinical Trial Pipeline Analysis: 40+ - GlobeNewswire","headline":"Complement Inhibitors Clinical Trial Pipeline Analysis: 40+","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6wFBVV95cUxQUjduT0hteXNsUHJDNi10SVp1cUUyWjFyeTdhdGxyWVBFM1U5Q0RhUmk1OWpfRWJTYjRlRE93TlQ0UE5vU0lqbERiVVdHd3BTd0NBOGUyTGR1WS11b083MGQtVTFibm5UTE1KbFlaYWVqLTRLdEZTaWdjZk5KZ0ZhaWtBR1dDVG13N0ROUmZ2c28zVm9yTjdiSUg0WDJCclp3dURPcEZXczN0YllqcS1FaUsxbWxOeDJlaFpBMWZ1RWlIUU5tdmxyaDJtWW1oQ3ZMRzBLRjk2THM1SUI0aVBzLS1aUDJYYkw5NUJv?oc=5","date":"2020-07-13","type":"pipeline","source":"European Medical Journal","summary":"Moving from The Periphery to The Core of The Matter – Where Does Opicapone▼ Fit in Parkinson’s Disease? - European Medical Journal","headline":"Moving from The Periphery to The Core of The Matter – Where Does Opicapone▼ Fit in Parkinson’s Disease?","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_3":1,"marketed":1},"enrichmentLevel":0,"visitCount":6,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}